NCT06629155Not yet recruiting
Studying Eye Movement Deficits and Cognitive Impairment in Patients with Multiple Sclerosis Using Infrared Eye Tracking and Cognitive Tests
Disentangling Cognitive Functioning and Visual Scanning Deficits in Cognitive Test Results in Multiple Sclerosis (MS)
Source: ClinicalTrials.gov · Last updated 6 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to study the relationship between cognitive problems and problems in eye movements in Multiple Sclerosis (MS). The main questions it aims to answer are: * What is the correlation between eye movement parameters (VDI AUC and VDI Pv/Am, left and right) and SDMT scores in patients with MS? * What is the number of patients with VDI AUC\>1.174 and/or VDI Pv/Am\>1.180 assessed by infrared oculography during prosaccades at 15 degrees left or right? * What is the correlation between eye movement parameters (VDI AUC and VDI Pv/Am, left and right) and cognitive test scores in patients with MS? Participants will perform specific cognitive tests and eye movements will be measured through infrared oculography. The primary hypothesis for the study is: participants who exceed the treshold (VDI AUC\>1.174 and/or VDI Pv/Am\>1.180, left or right) will perform worse on cognitive tests compared to those who don't.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 1 Oct 2024
- Start date
- Mar 2025
- Primary completion date
- Feb 2027
- Lead sponsor
- Universitair Ziekenhuis Brussel
- Diseases
- Multiple sclerosis
- NCT number
- NCT06629155
What you commit to
- Study type: Observational
- Planned participants: 50
- From Mar 2025 to the primary completion date, Feb 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Start or switch in immunomodulatory treatment within three months before inclusion.
Other illness
- Major medical or psychiatric pathology that potentially affects cognitive functioning.
Other
- A score higher than 63 on the Fatigue Scale for Motor and Cognitive Functions is categorized as severe fatigue
- Less than 3 months post exacerbation.
- Refusing informed consent.
Who the study is looking for
- Diagnosed with clinically definite multiple sclerosis according to the 2017 McDonald criteria
- At least 18 years old
- Combined vision with optimal correction \> 0,6 on Snellen Visual Acuity Test.
- Providing informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.